The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a huge mover today! About 88,219 shares traded hands. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 75.49% since March 7, 2016 and is uptrending. It has outperformed by 67.90% the S&P500.
The move comes after 9 months positive chart setup for the $536.23 million company. It was reported on Oct, 10 by Barchart.com. We have $33.96 PT which if reached, will make NASDAQ:BLCM worth $348.55 million more.
Analysts await Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings on November, 14. They expect $-0.62 EPS, down 21.57% or $0.11 from last year’s $-0.51 per share. After $-0.61 actual EPS reported by Bellicum Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 1.64% negative EPS growth.
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Ratings Coverage
Out of 6 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. Bellicum Pharmaceuticals Inc has been the topic of 9 analyst reports since July 24, 2015 according to StockzIntelligence Inc. On Friday, September 11 the stock rating was upgraded by Guggenheim to “Buy”. As per Thursday, February 25, the company rating was initiated by Citigroup. The rating was initiated by SunTrust with “Buy” on Friday, June 3. The rating was initiated by Suntrust Robinson on Friday, June 3 with “Buy”. The rating was downgraded by Zacks on Monday, September 21 to “Sell”. The rating was maintained by Citigroup on Tuesday, August 9 with “Neutral”. Citigroup initiated the stock with “Buy” rating in Friday, July 24 report. The firm has “Hold” rating given on Wednesday, August 19 by Zacks. Jefferies maintained Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) on Tuesday, August 9 with “Buy” rating.
According to Zacks Investment Research, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.”
More notable recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on December 18, 2014, also Fool.com with their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.” published on June 26, 2016, Fool.com published: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” on August 03, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) were released by: Quotes.Wsj.com and their article: “News Bellicum Pharmaceuticals Inc.BLCM” published on December 13, 2014 as well as Businesswire.com‘s news article titled: “Bellicum Pharmaceuticals Announces Patent on CaspaCIDe Method for Selectively …” with publication date: July 20, 2016.
BLCM Company Profile
Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.